(b) Trial sites
The TRACT trial recruited children from Uganda (Mbale Regional Referral Hospital, Soroti Regional Hospital, and Mulago Hospital, Kampala) and Malawi (Department/College of Medicine and Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre).
(c) Further details of randomisation to cotrimoxazole
Cotrimoxazole was provided as dispersible tablets (240mg: trimethoprim 40 mg/sulphamethoxazole 200mg). Dosing followed WHO recommendations for prophylaxis in HIV-infected children, namely 120mg for those aged 2-6 months; 240mg 6 months to 5 years; and 480mg for those >5 years. The dispersible tablets could be taken with water or mixed with feeds.
The cotrimoxazole prophylaxis randomisation was pragmatic in that all children for whom cotrimoxazole prophylaxis should have been prescribed according to WHO or national guidelines (e.g. HIV-infected children) received it regardless of randomisation, and no child in whom it was contraindicated (e.g. known GP6D deficiency according to local testing) received it. The number of children with these conditions was expected to be small (<5%). Such children essentially ignored the cotrimoxazole randomisation on their allocated card; any cotrimoxazole received per guidelines was recorded on case record forms.
At the time of the trial there was no national policy regarding cotrimoxazole supplementation in children with known sickle cell disease (SCD) in Uganda -national guidelines recommended pencillin V for children with SCD under 5 years of age, and malaria prophylaxis with chloroquine. Malawi had no guidelines as sickle cell is rare.
(d) Further details of randomisation to multi-mineral multivitamins (MVMM) and iron/folate
MVMM was provided as Nutromix TM1 (see product specification in appendix), which was specifically designed to meet the recommended nutrient intake (RNI) for children 6-24 months of age with severe anaemia, defined as the daily dietary in−take of a nutrient sufficient to meet the nutrient requirements of nearly all apparently healthy individuals in a specific population group, usually by age and sex. Nutromix has been widely used, for example in studies in children in Ghana 2,3 and Kyrgyz, 4 and in pregnant women. 5
Micronutrients
Per One sachet was taken daily by the child, mixed into any semi-solid or semi-liquid food, after the food has been prepared and cooled to a temperature acceptable to eat (less than 60 0 C).
The control group received iron syrup or tablets and folate tablets following WHO guidelines for the management of severe anaemia using local standard-of-care: namely 25mg iron and 100-400micrograms folate daily for children <2 years (depending on the local formulation); and 60mg iron and 400micrograms folate daily for >2 years and <12 years.
The nutritional supplementation, including MVMM randomisation, was pragmatic in that all children for whom these supplements should have been received according to WHO or national guidelines (e.g. those initially admitted with severe malnutrition) received them, and children who should not have received them (e.g. children with severe malnutrition who should not receive iron-containing supplements in the first 7 days of acute rehabilitation) did not receive them. Children with severe malnutrition discharged on ready to use food supplements (RUTF) which contain MVMM essentially ignored the MVMM randomisation on their allocated card, but received their standard postdischarge supplementation within the RUTF which was recorded on case record forms. The number of children with severe malnutrition as their admission diagnosis was expected to be <5%. Children < 6 months who were not weaned (fully breast feed) and therefore could not take MVMM were excluded from the trial. 
Recommended nutrient intakes (RNI) with assumed bioavailability of 10%

(e) Further details of allocation concealment
Trial numbers and associated randomized allocations (to all four factorial randomizations) were kept inside opaque sealed envelopes, packed at Kilifi, Kenya, as were separate consecutively numbered packs containing case record forms and a link to one specific opaque sealed envelope containing a trial number and randomized allocation. The link between pack number and trial number (and hence randomized allocation) was also randomized within blocks. At enrolment, trial staff opened the next consecutively numbered pack, which directed them to a sealed randomization envelope which was within the next 16 envelopes, but was not the next one, ensuring allocation concealment. This method was used to ensure that acutely unwell children could be treated immediately at the emergency ward, without having to rely on a computer or the internet to obtain a randomized allocation.
(f) Further details of endpoint ascertainment and adjudication
SAEs were defined following the International Committee for Harmonisation as events which led to death, were lifethreatening, caused or prolonged hospitalization (excluding elective procedures), caused permanent disability, or were other medical conditions or with a real, not hypothetical risk of one of the previous categories.
Deaths (including causes) and trial-drug relatedness were adjudicated by an Endpoint Review Committee (ERC) (two members independent of day to day running of the trial) blind to volume of transfusion and trial drugs received, using the available clinical/laboratory data provided by the sites. They also reviewed all suspected transfusion reactions, suspected respiratory events, suspected neurological events, and allergic reactions.
(g) Sample size calculation from the trial protocol
The sample size calculation was based on 80% power and 2 sided alpha=0.013 to allow for 4 comparisons (factorial randomisations to post-discharge MVMM and/or cotrimoxazole, reported here, plus additional randomisations to 30mls/kg vs 20mls/kg whole blood equivalent transfusion and to any vs no transfusion in those with haemoglobin >4g/dl and no severity signs; uncomplicated severe anaemia). The calculation assumed cumulative mortality at 6 months (primary endpoint for this comparison) would be 28.5% in the complicated severe anaemia stratum, and 21.5% in the uncomplicated severe anaemia stratum, with a 1:1 ratio enrolled in these two subgroups, leading to overall mortality of 25% in those randomised to standard supplementation or no cotrimoxazole prophylaxis. A total of 3162 children provided 80% power to detect a 5% absolute reduction (to 20%), inflated to 3364 assuming 6% lost to follow-up by 6 months. 3954 severe anaemia cases were required to provide >80% power for the transfusion comparisons, so the total sample size enrolled allowed for dilution effects due to a small percentage of children pragmatically not following their allocated MVMM or cotrimoxazole strategy (see (b) and (c) above) and for children dying in hospital or absconding never starting their allocated supplementation.
(h) Statistical methods
The primary analysis was intention-to-treat based on all randomised participants. Randomisation was done at admission, given the relatively low resourced district hospitals in which the trial was undertaken, necessitating the use of envelope-based allocation concealment. Practically, it was not judged feasible to do a second set of randomisations at discharge, and there was also the potential to confuse different sets of randomisation envelopes. Compared to a second randomisation at discharge, the intention-to-treat estimate of intervention effect between groups randomised at admission would have a small amount of dilution bias. A secondary analysis (prespecified in the Statistical Analysis Plan) therefore restricted the population to patients alive at the minimum of discharge or 5 days from randomisation in whom these interventions were neither mandated nor contraindicated (ie excluding HIV-infected children and those with known GP6D deficiency or other contraindications from the cotrimoxazole randomisation, excluding children admitted for severe acute malnutrition, already taking ready-to-use supplementary food or with other contraindications from the supplementation randomisation). Of note, this population is not randomised, because exclusions are based on post-randomisation factors, and therefore this analysis is not formally intention-to-treat. However, the trial was implemented using a factorial design: that is, each randomisation was intrinsically balanced for every other randomisation. Therefore had, for example, more deaths occurred in one transfusion group, balance would still be maintained across both the MVMM and cotrimoxazole randomisations, meaning there is no selection bias in the intention-to-treat comparison of groups as randomised at admission. Any differences in characteristics in the small number of children who died/absconded before discharge (3%) could potentially lead to a small difference in baseline characteristics between those randomised and those who survived to take the MVMM/cotrimoxazole interventions; the impact of this was assessed using standard subgroup analyses (see below), Time-to-event analyses measured time from randomization, censored at the last ascertainment of vital status if the outcome or any competing events had not occurred. For analyses concerning events at specific time points, surviving children were censored at that time point; specifically for analyses at 28 days, censoring occurred on day 28, for analyses at 90 days censoring occurred on day 90 and for analyses at 180 days censoring occurred on day 183 as this corresponded to 6 months. Analyses of time to readmission measured time from discharge. The primary analyses stratified for randomization stratification factors (centre, stratum) using stratified logrank test and stratified Cox regression; results from secondary unstratified analyses were very similar (data not shown). Lost-to-follow-up was defined as unknown vital status despite contact tracing by sites.
Analyses of causes of death, and all time-to-event outcomes which did not include all-cause mortality, used competing risks methods. These estimated the probability of the event (analogous to Kaplan-Meier) using cumulative incidence functions, and estimated the effect of randomized group on the sub-distribution hazard corresponding to the cumulative incidence function 7 . For time to haemoglobin recovery and new profound anaemia, death and discharge were considered as competing events. For new profound anaemia, children were only at risk after having one haemoglobin measurement above 4g/dl. These analyses were conducted unstratified, as stratification is not possible with the estimating equation approach used for estimation.
Haemoglobin was compared between randomized groups over time using generalised estimating equations (GEE) (independent correlation structure) with randomized group, adjusting for stratification factors and scheduled visit week as categorical independent variables. The closest measurement to each scheduled visit date within equally spaced windows was used as the measurement at each scheduled visit. Continuous measurements were modelled using change from baseline as the outcome in a normal GEE model, adjusting for baseline value. Haemoglobin below or above thresholds was modelled as a dichotomous outcome in a poisson GEE model to estimate rate ratios. Comparisons at individual timepoints were undertaken using equivalent models without adjusting for repeated measures. Baseline values were those taken at screening.
For each of the primary and secondary outcomes, interactions with the other factorial randomisations (post-discharge cotrimoxazole or multi-vitamins multi-minerals, 20 vs 30 mls/kg transfusion, any vs no transfusion) were tested by including interaction terms in the final model as above.
No adjustment was made for multiple testing.
(i) Subgroup analyses
We pre-specified in the protocol eleven subgroup analyses by the other factorial randomizations (multi-vitamins multi-minerals vs iron and folate, cotrimoxazole vs none, 20 vs 30 mls/kg transfusion, any vs no transfusion; 3 interactions relevant for each randomisation presented here); stratification factors (centre, complicated vs uncomplicated severe anaemia); and six other key factors (previous transfusion ever, fever at screening (temperature >37.5°C), malaria, known sickle cell disease on enrolment or sickle cell disease positive on blood test at admission, HIV (not for the cotrimoxazole vs none comparison as HIV positive children were expected to be prescribed cotrimoxazole following guidelines), and microbiological evidence of sepsis (blood culture or retrospective molecular diagnosis)).
A further five subgroup analyses were pre-specified in the Statistical Analysis Plan, namely by haemoglobinurea, malnutrition, shock (one of weak pulse volume, temperature gradient or capillary refill time), hypothermia, and dehydration.
For continuous factors, we considered both categorisation and natural cubic splines (five knots at the 10 th , 25 th , 50 th , 75 th , and 90 th centiles) to test for interactions with the main intervention effect of 30mls/kg vs 20mls/kg. All subgroup analyses were conducted unstratified to avoid losing information from small strata with no events in one randomized group. 
SUPPLEMENTARY FIGURES
Figure S11 Impact of MVMM on haemoglobin recovery post-discharge by receipt of blood transfusion in TRACT B only
Note: restricted to children with haemoglobin 4-6g/dl and no severity signs enrolled in TRACT B who were randomised to immediate vs triggered transfusion. Triggered transfusion group split (non-randomised) into those who did vs did not receive a transfusion triggered by new severity signs.
There was no evidence of a differential effect of MVMM vs iron/folate according to immediate vs triggered received vs triggered no transfusion received groups (ie no evidence of interaction) at 28 days (p=0.83), 90 days (p=0.75) or 180 days (p=0.63) adjusting for predictors of receiving a transfusion (baseline haemoglobin, age, heart rate and centre).
Figure S12 Impact of MVMM on malaria by age group (varying dosage of iron)
(a) Positive malaria slide Note: All events had independent clinical review and none were adjudicated to be probably or possibly related to the interventions. 
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